How a Novel Molecular Screening Technology for Blood-Related Cancers Can Provide Operational and Cost-Effective Benefits to Your Lab
FREE LIVE WEBINAR WITH Q&A
Wednesday, June 9 | 1 pm EDT
Yes, there is an alternative to the traditional blood-related cancer testing modalities
Current molecular testing modalities for blood-related cancers are cumbersome to operate and subsequently generate poor economics—forcing laboratories to batch large samples, resulting in slow turnaround time, or avoid the process entirely and send these tests out. HemeScreen is a novel, proprietary technology that offers an alternative to the existing testing modalities and an opportunity for laboratories to bring tests in-house that have otherwise not been economically viable.
During this complimentary webinar with follow-up Q&A, How a Novel Molecular Screening Technology for Blood-Related Cancers Can Provide Operational and Cost-Effective Benefits to Your Lab, you will learn about the technology, efficient workflow, and profit potential of HemeScreen.
How one practice implemented this new testing solution
Precipio’s leadership team—Medical Director Frank Bauer, MD, CTO Ayman Mohamed, MD, and CEO Ilan Danieli—will discuss the clinical, operational, and economic impact of implementing HemeScreen and present a case study to share how a five-physician practice on the East Coast implemented HemeScreen in its office laboratory and continues to evolve with the technology. You will hear why the practice adopted HemeScreen, the setup and workflow involved, the outcomes the practice has experienced so far, and the plans for expansion.
By attending this webinar, you will understand how HemeScreen provides operational and economic benefits including significantly reduced costs, ease of adoption, simple and streamlined workflow, and the ability to run smaller batches with attractive economics—resulting in decreased turnaround time, better patient care via faster TAT, and improved profit margins for laboratories. In addition, you will be able to explore how adopting HemeScreen can improve your lab’s operational efficiencies and profit margins and ultimately deliver better service to your physician customers and their patients.
With this 60-minute program, you will:
- Understand the differences between current technologies used and HemeScreen—and their advantages and disadvantages relative to HemeScreen
- Hear about HemeScreen’s operational impact on the lab in terms of workflow, TAT, and economics
- Learn about HemeScreen’s ease of adoption and implementation into lab workflow
- Understand the clinical effects of HemeScreen to the customer (the treating oncologist)
- Have the opportunity to pose specific questions and connect directly with the panel during a Q&A session
Who should attend?
- Molecular laboratory managers and staff
- Molecular pathologists
- Laboratory operations managers
HemeScreen can empower your laboratory to deliver substantial clinical benefits to your oncology customers, enable you to follow updated clinical guidelines, and expand your test offering while reducing turnaround time. Together, these benefits ultimately provide higher quality diagnostic information to oncologists and their patients.
Frank Bauer, MD
New Haven, CT
Dr. Bauer has served as Precipio’s Medical Director since 2018. He completed his residency in anatomic and clinical pathology and hematopathology fellowship at Walter Reed Army Medical Center. He was appointed as Director of Hematopathology at Walter Reed after completing his fellowship, with sign-out and resident teaching responsibilities and involvement in hematology research and publications in conjunction with the Armed Forces Institute of Pathology (1988-1996). Dr. Bauer joined the pathology staff at Saint Francis Hospital and Medical Center in 1996 as Director of Hematopathology and taught medical students at UCONN and Quinnipiac Medical Schools (1996-2018).
Ayman Mohamed, MD
Chief Technical Officer
New Haven, CT
Dr. Mohamed, one of Precipio’s co-founders and Chief Technical Officer, is responsible for conceptualizing and inventing proprietary technologies, design, and development; economic cost analysis and modeling; testing and validation; and the technical implementation of the technologies for clinical use in Precipio’s laboratories. Before co-founding Precipio, Ayman served in technical and research positions at commercial diagnostic companies and academic centers such as Columbia and Yale University. He holds an MD from the University of Alexandria and a master’s degree in human genetics.
New Haven, CT
Ilan Danieli, Precipio’s CEO since co-founding the company in 2011, has managed small-and medium-sized companies for more than 20 years. His previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the U.S., Canada, and Europe; VP of Operation at Laurus Capital Management; and other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia and a BA in Economics from Bar-Ilan University in Israel. In addition, he served in the Israeli military as a tank commander.